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Malignant gliomas are both highly vascular and invasive tumours;
tumour cells commonly invade several centimetres beyond the
main tumour mass at the time of diagnosis. These features render
them surgically incurable and existing treatments only modestly
prolong survival. Both invasion and neovascularization require
extracellular matrix (ECM) breakdown and the subsequent migra-
tion of cells through the degraded structures (Liotta et al, 1991).
Since ECM remodelling is the principal activity of a family of
enzymes known as matrix metalloproteinases (MMPs), these
enzymes have come under investigation for their contributions to
the malignant phenotype of gliomas (Uhm et al, 1997; Yong et al,
1998; Price et al, 1999; Raithatha et al, 2000). 
There are currently 23 known members of the MMP family
which are subdivided according to their structures and substrate
specificities into membrane-type matrix metalloproteinases (MT-
MMPs), collagenases, stromelysins and gelatinases (Murphy and
Knäuper, 1997; Nagase and Woessner, 1999). Controlled MMP
activity is essential to numerous physiological processes such as
wound healing and bone development. However, when MMP
activity goes unchecked, excessive tissue destruction occurs,
leading to a myriad of pathological states including tumour inva-
sion and metastasis. The MMPs are tightly regulated at several
levels, including transcriptional induction, activation of inactive
zymogens, and inhibition by tissue inhibitors of metallopro-
teinases (TIMPs). An imbalance between MMP and TIMP activity
may contribute to the malignant behaviour of many cancers
(Chambers and Matrisian, 1997). In particular, Gelatinase-A
(MMP-2) and the MT-MMPs that activate it on the cell surface
have been linked with both tumour cell invasion and angiogenesis
(Yamamoto et al, 1996; Hiraoka et al, 1998; Belien et al, 1999;
Forsyth et al, 1999; Llano et al, 1999; Nakada et al, 1999; Price 
et al, 1999; Raithatha et al, 2000). 
The TIMP family is comprised of 4 gene products (TIMPs 1–4)
which inhibit secreted MMPs with roughly comparable potencies
(Apte et al, 1995; Greene et al, 1996; Blavier et al, 1999).
Individual TIMPs differ markedly in their pro-MMP interactions
and gene regulatory mechanisms. For example, TIMP-1 specifi-
cally interacts with pro-gelatinase-B and is subject to tight control
at the level of transcription (Phillips et al, 1999), whereas TIMP-2
binds pro-gelatinase A and shows constitutive gene expression
(Blavier et al, 1999). Differences also exist with regard to
biochemical properties: TIMP-3 is itself an ECM-associated
protein but TIMP-1, -2 and -4 are freely diffusible (Leco et al,
1994). Moreover, TIMP-1 is ineffective as an inhibitor of MT1-
MMP, whereas TIMP-2 and TIMP-3 are both functional in this
regard (Will et al, 1996). 
There is broad support for the notion that TIMPs in general act
as ‘brakes’ on the malignant process. Thus, antisense-mediated
down-regulation of TIMP-1 can induce tumorigenic and
metastatic behaviour in mouse fibroblasts (Khokha et al, 1989)
and exogenous or overexpressed TIMP-1 and TIMP-2 reduce
tumour invasion and metastasis and in vivo (DeClerck et al, 1991,
1992). TIMP-3 down-regulation has been noted at the invasive
edge of highly aggressive colorectal carcinomas (Powe et al,
1997), and overexpressed TIMP-4 resulted in decreased invasive
capacity of breast carcinoma cells (Wang et al, 1997). 
This classical notion of TIMPs in tumour biology is rather
narrow, however, and there is a growing appreciation that these
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example, TIMP-1 stimulates the proliferation of erythroid precur-
sors (Gasson et al, 1985), and both TIMP-1 and TIMP-2 can posi-
tively influence the proliferation of numerous cell types
(Hayakawa et al 1992, 1994; Wingfield et al, 1999). Additionally,
TIMP-2 inhibits in vitro proliferation of human microvascular
endothelial cells stimulated with bFGF (Murphy et al, 1993), and
TIMP-3 promotes apoptosis (Ahonen et al, 1998; Baker et al,
1998), possibly through stabilization of TNF alpha receptors
(Smith et al, 1997). High TIMP-1 levels have been linked with
increased malignancy in human lymphomas (Kossakowska et al,
1991; Stetler-Stevenson et al, 1997) and colorectal cancer (Zeng 
et al, 1995; Holten-Anderson et al, 1999). These studies suggest
that TIMPs have a variety of functions beyond MMP inhibition,
though their precise role in other cellular processes remains
unclear. 
There is a wealth of evidence showing that MMPs are overex-
pressed in malignant gliomas but studies of TIMPs in gliomas give
conflicting results. Reduced expression of TIMP-1 and -2 with
increasing glioma grade has been reported, suggesting that a lack
of inhibitor expression may contribute to a more aggressive
glioma phenotype (Mohanam et al, 1995; Kachra et al, 1999).
However others report an upregulation of TIMP-1 or -2 expression
in malignant tumours (Nakano et al, 1995; Saxena et al, 1995;
Lampert et al, 1998). No studies have described the expression of
TIMP-4 in human brain tumours. 
To gain further insight into how TIMPs might be involved in
glioma pathophysiology, we examined the mRNA and protein
expression of TIMPs 1–4 in human normal brain and glioma
surgical specimens. We found that TIMPs -1 and -4 expression
correlated with glioma malignancy in a positive and negative
manner respectively. Localization studies showed different cellular
distribution patterns for these 2 genes, with TIMP-1 transcripts
strongly localized to vascular structures, while both TIMP-1 and -4
localized to tumour cells. Our results suggest that deregulated
expression of TIMP-1 and -4 may contribute to glioma malig-
nancy, and point to unique roles for these proteins during glioma
tumorigenesis. 
METHODS 
Tissue collection 
Procedures were performed under a general anaesthetic. Induction
consisted of a combination of pentothal, fentanyl, and vecuronium
with maintenance achieved using isoflurane and intermittent
fentanyl as needed. During the craniotomy, mannitol (1 g kg–1)
was administered for cerebral decompression. Tumour specimens
were obtained prior to thermal coagulation and placed immedi-
ately in liquid nitrogen and stored at –80˚C in the Neuro-specimen
Tumour Bank. The study has been approved by the ethics board of
the Faculty of Medicine, University of Calgary. All patients gave
signed, informed consent for their tissue to be used. The following
non-irradiated, newly diagnosed tissues were studied from the
tumour bank: 19 glioblastoma multiforme (GBMs), 7 anaplastic
astrocytomas (AA), 5 malignant oligodendrogliomas (MO), 8 low-
grade gliomas (LG): these were compared to 4 controls (2 from
frozen tissue from surgery unconnected with glioma and 2
obtained at autopsy). 
Cell culture 
U87 and U251 cell lines were obtained from ATCC (American
Type Culture Collection, Rockville, MD, USA). These cells were
grown in Dulbecco’s Modified Eagle’s Medium-Ham’s F12
(DMEM-F12) containing 10% (vol/vol) fetal calf serum. Cells
were passaged after reaching approximately 80% confluency,
harvested by trypsin treatment and replated in DMEM-F12/10%
FCS. 
Primary HUVECs were obtained from TCS Biologicals
(Buckingham, UK) and grown on type I collagen (60 mg ml–1)
coated tissue culture plastic, in medium supplied by the manufac-
turer. For analysis of gelatinase levels in conditioned media,
HUVECs were seeded on type I collagen (60 mg ml–1) coated 24
well plates at a density of 1 ´ 105 cells per well. The following day,
cells were washed twice with serum-free medium and incubated in
fresh serum-free medium with or without stimulation with 10–7 M
phorbol myristoyl-13 acetate (PMA; Sigma-Aldrich, Poole, UK)
for 24 hours. The conditioned medium was then collected,
centrifuged at 7000 rpm for 10 minutes to remove any cells 
in suspension, and 50 mM Tris pH 8.0 was added and stored 
at –20˚C. 
RNA and protein preparation 
Total RNA was extracted using the acid guanidinium isothio-
cyanate method. The final RNA concentrations were determined
by absorption at 260 nm using a GeneQuant spectrophotometer
(Pharmacia). Protein extraction involved homogenization of tissue
in extraction buffer (0.5 M Tris-HCl, pH 7.6, containing 0.2 M
NaCl, 10 mM CaCl2, and 1% Triton X-100). The homogenate was
centrifuged at 4˚C for 15 minutes at 15 000 g and supernatant was
stored at –70˚C for Western blot and reverse zymography assays. 
Reverse transcription reactions 
Each 20 ml cDNA synthesis reaction contained 1 mg of total RNA,
1 ´ PCR buffer (10 mM Tris-HCl, pH 9.0, 50 mM KCl, 1.5 mM
MgCl2), 1 mM of each deoxyribonucleotide triphosphate,
20 U placental ribonuclease inhibitor (RNAguard, Pharmacia),
160 units of MuLV-reverse transcriptase (Bethesda Research
Laboratories) and 100 pmol of random hexamer oligodeoxy-
nucleotides (Pharmacia). Reaction mixtures were pre-incubated
10 min at 21˚C prior to cDNA synthesis. Reverse transcription
was carried out for 50 min at 42˚C and then heated to 95˚C for
5 min to terminate the reaction. Samples were stored at –20˚C
until use. 
Polymerase chain reactions 
Multiplex PCRs were performed in 50 ml reaction volumes. Each
reaction contained 2 ml of RT reaction product, 1 ´ PCR buffer, 
80 mM of each deoxynucleotide, and 20 pmol of each 5¢ and 3¢
primer pair (see Table 1). 2 units of Taq DNA polymerase (Gibco-
BRL) were added to each tube during the first denaturation step
(‘hot start’) and equal aliquots (20 pmol) of GAPDH primer sets
were added at the appropriate cycle number by the primer-drop-
ping method (Wong et al, 1994). The primer-dropping method for
quantification of MMP and TIMP RNA levels has been described
in detail (Wong et al, 2000). Each PCR cycle consisted of a heat
denaturation step (94˚C for 1 min), a primer-annealing step at
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Reactions were performed in a Temp-Tronic Thermal Cycler
(Barnstead/Thermolyne). PCR products were electrophoresed
through a 2% agarose gel containing 0.2 mg ml–1 ethidium
bromide. Band intensities were calculated by scanning densitom-
etry (NIH imaging program), and TIMP to GAPDH ratios for each
sample were plotted as a function of tumour grade. Results were
expressed as the mean ± standard deviation. 
Western blotting 
20 mg of protein from glioma cell line conditioned medium were
mixed with 33 SDS gel-loading buffer (0.188 mM Tris-HCl 
(pH 6.8), 3% SDS (w/v), 0.0075% bromophenol blue, 30% glyc-
erol and 3% b-mercaptoethanol) and separated on a 12%
polyacrylamide gel. After transfer to a nitrocellulose membrane,
blots were blocked in 5% nonfat milk overnight at RT, and then
incubated with 1 ng ml–1 rabbit anti-human TIMP-4 antibody
(Chemicon). After incubation with peroxidase labelled secondary
antibodies, signals were detected using an enhanced chemilumi-
nescence detection system (Amersham). For cell fractionation
studies, glioma cells were washed twice in ice-cold PBS without
Ca2+ and Mg2+ and then suspended in 1 ml hypotonic lysis buffer
(10 mM Tris-HCl (pH 8.0), 0.2 mM KCl, 1 mM PMSF and 10 mg
ml–1 aprotinin and leupeptin). Cells were lysed by dounce homog-
enization and samples were adjusted to a final concentration of
0.25 M sucrose, 1 mM EDTA, and nuclei and unlysed cells were
removed by low speed centrifugation (10 min at 1000 g).
Membrane and cytosol fractions were prepared from the postnu-
clear supernatant by centrifugation at 100 000 g for 1 h at 4˚C. The
supernatant (cytosol) was removed and the remaining pellet
(membrane fraction) was solubilized in SDS sample buffer. Both
cytosol and membrane fractions were then analysed on Western
blots as above. 
Gelatin zymography 
MMP activity in the conditioned medium of cultured HUVECs
was analysed by substrate gel electrophoresis (zymography), using
a 10% polyacrylamide gel co-polymerized with 1 mg ml–1 gelatin
(Sigma). Equal amounts of samples were mixed with 1% (w/v)
SDS sample buffer under non-reducing conditions and loaded onto
the gel (resolving gel: 17.5 cm ´ 10.5 cm). Gels were run using a
V15–17 GibcoBRL vertical gel electrophoresis apparatus, at 
20 mA until the bromophenol blue dye traversed into the resolving
gel. The current was then increased to 30 mA and the gels were
electrophoresed until 1 hour after the bromophenol blue dye had
run off the gel. The gels were then washed in 50 mM Tris-HCl, 
5 mM CaCl2 (pH 8.0) and 2.5% (v/v) Triton X-100 overnight and
then incubated in 50 mM Tris-HCl, 5 mM CaCl2 (pH 7.5) for 18
hours at 37˚C. Gels were stained with Coomassie blue and
destained in 10% acetic acid and 10% isopropanol. Gelatinolytic
activity appears as a clear band on a blue background. 
cRNA probe preparation 
TIMP-1: A 185 bp HindIII/BamHI fragment of human TIMP-1 in
pBluescript II KS– was used to generate antisense and sense ribo-
probes using T3 polymerase/Bam HI and T7 polymerase/Xho I
digested plasmid respectively. TIMP-4: A 400 bp HindIII/BamHI
fragment of murine TIMP-4 in pBluescript II KS– (Leco et al,
1997) was used to generate antisense and sense riboprobes using
T3 polymerase/Bam HI and T7 polymerase/Hind III digested
plasmid respectively. Riboprobes were prepared and labelled with
digoxygenin (DIG)-labelled-UTP (Roche, Laval, Quebec, Canada)
following the manufacturer’s instructions. 
In situ hybridization 
Tissue sections were deparaffinized using xylene and rehydrated
through a graded ethanol series (100%, 95%, 80%, 70% respec-
tively). After proteinase K treatment at 37˚C for 25 min and acety-
lation using a solution of 0.5% acetic anhyride in 0.1 M
triethanolamine, pH 8.0, tissues were prehybridized for 2 hours at
50˚C (50% formamide, 5 3 SSPE, 1 3 Denhardt’s solution) and 
20 ng of probe (diluted in prehybridization buffer with 8 mg ml–1
E. coli tRNA) was added. Sections were incubated at 60˚C
overnight. Sections were washed in 2 X SSC and were incubated
in 20 mg ml–1 RNAse A at 37˚C for 45 min. After washing in a
graded SSC series (2X, 1X, 0.5X, and 0.1 X (60˚C)) sections were
incubated in blocking buffer containing lamb serum for 2 hours.
Anti-DIG antibody was added at a concentration of 3/500 and
slides were left for 4 hours at room temperature. NBT/BCIP chro-
mogens were applied to sections and colour was developed in the
dark. When the desired intensity was reached, the colour reaction
was terminated by placing sections in 20 mM Tris-HCl pH 7.5,
10mM EDTA. Sections were mounted with Kaiser’s medium.
Photographs were taken using Kodak Royal Gold 35 MM film
under a Ziess photomicroscope II under bright field illumination. 
Transfections 
Mouse TIMP-4 cDNA (675 base pairs; Leco et al, 1997) was
cloned into the EcoRI site of the pBabe-puro. TIMP-4 containing
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Table 1 RT-PCR primers and conditions for TIMP expression analysis 
Target gene Primer sequence (5¢ ¢–3 ¢ ¢) Target accession number Position Product size (bp) PCR cycle No. 
TIMP- 1 AGCGCCCAGAGAGACACC X03124.1  33–50 670 25–26 
CCACTCCGGGCAGGATT 702–686 
TIMP-2 GGCGTTTTGCAATGCAGATGTAG NM  003255.1 378–400 497 30–32 
CACAGGAGCCGTCACTTCTCTTG 874–852 
TIMP-3 CTTCTGCAACTCCGACATCGTG NM 000362.1 389–410 459 22–23 
TGCCGGATGCAGGCGTAGTGTTT 847–825 
TIMP-4 AATCTCCAGTGAGAAGGTAGTTCC NM 003256.1 212–235 512 31–32 
CGATGTCAACAAACTCCTTCCTGA 723–700 
GAPDH CGGAGTCAACGGATTTGGTCGTAT M33197 78–101 307 22–23 
AGCCTTCTCCATGGTGGTGAAGAC 384–361 plasmids were introduced into U87 cells using the Calcium
Phosphate Transfection Kit (Sigma) following the manufacturer’s
instructions, and cells were grown in DMEM F12/10% FCS selec-
tion medium with 20 mg ml–1 puromycin. Cloning rings were used
to isolate viable clones and functional expression of the TIMP-4
insert was confirmed using reverse zymography and Western
blots. 
Invasion assay 
Matrigel was thawed at 4˚C on ice overnight. Using cooled pipette
tips, matrigel (5 ml) was mixed with 0.5% FBS (25 ml) and spread
evenly in wells of a 24-well Boyden chamber containing 8 mm
pore polycarbonate filters. Matrigel was allowed to solidify for 30
min at 37˚C. Cells were then seeded at a density of 2.5 ´ 105 ml–1
into each chamber and covered with 200 ml of media (0.5% FBS)
containing the desired concentration of inhibitor. Chambers were
set into 700 ml of fibroblast media (ensuring no bubbles were
caught under the chamber) and incubated for 24 h at 37˚C.
Chambers were rinsed in PBS and cells were scraped off the top of
the membrane using a cotton-tipped swab. Cells were fixed to the
bottom of the chamber using cold methanol for 2 min and then
stained in haematoxylin before mounting on slides with Kaiser’s
mounting media. 
RESULTS 
Analysis of TIMP gene expression in gliomas 
To determine the relationship between TIMP expression and
glioma aggressiveness, specimens from normal brain and tumour
were analysed using RT-PCR. Total RNA was extracted from
surgically obtained specimens, and each sample was amplified by
PCR in 3 separate assays to ensure consistent results. GAPDH was
used as an internal control in individual PCR reactions to monitor
input levels of cDNA. 
A representative profile for each of the 4 TIMPs is shown in
Figure 1A and the combined quantified data for all of the tumour
samples and normal brain specimens are shown in Figure 1B.
When comparing the expression patterns of the 4 transcripts, only
TIMPs-1 and -4 showed a correlation with glioma malignancy
over the range of tumour grades. For TIMP-1, expression was
barely detectable by RT-PCR in normal brain tissue and lower
grade tumours, but increased dramatically for GBM tumours. In
contrast, TIMP-4 mRNA expression showed a negative correla-
tion with glioma grade, but was higher in tumours than normal
brain. Relative to the GAPDH signal in each PCR reaction, the
most intense TIMP-4 bands appeared for lower and middle grade
lesions, while the ratio diminished for GBM specimens; some
GBMs showed only a barely detectable TIMP-4 band. Whereas
TIMP-1 and -4 expression varied with glioma malignancy, levels
of TIMP-2 and TIMP-3 RNAs remained fairly constant over all
tumour grades examined. 
Localization of TIMP-1 and TIMP-4 using in situ
hybridization 
To determine the cellular origin and distribution of TIMPs-1 and -4
we performed in situ hybridization on paraffin-embedded glioma
and normal brain specimens. Adjacent sections were stained with
haematoxylin and eosin to facilitate pathological interpretation.
Strong localization of TIMP-1 transcript was seen in the cytoplasm
of malignant cells, with little or no staining seen in the cells of the
surrounding host stroma (Figure 2A). GBM sections also showed
intense staining for TIMP-1 transcripts around vascular structures
and within endothelial cells. This feature was noted in all high grade
sections analysed, and was absent in lower grade astrocytomas.
Normal brain showed low levels of expression only in neurons, and
the TIMP-1 sense control showed no signal (data not shown). 
Similar to TIMP-1, TIMP-4 transcripts were localized to malig-
nant cells; however, in contrast to TIMP-1 there was very little
signal from the TIMP-4 antisense probe in endothelial cells and
adjacent perivascular cells (Figure 2B). TIMP-4 RNAs were also
found in low-grade astrocytomas, and within the neurons of
normal brain tissue, and TIMP-4 sense controls showed no signal
(data not shown). 
Matrigel invasion assays 
The effects of TIMP-4 overexpression on in vitro invasion were
analysed using Matrigel coated Boyden chambers. As seen in
Figure 3A, two independent U87 clones transfected with pBabe-
TIMP-4 (T4–4 and T4–11) showed approximately 85% and 70%
decreased invasion compared to vector control (VC), which was
taken as 100% invasion. The T4–4 and T4–11 U87 clones showed
approximately 5-fold increased levels of TIMP-4 protein
compared to vector control tranfected cells (Figure 3B). TIMP-4
was present in conditioned media of glioma cells and as a cell-
associated protein (data not shown). Cell-associated TIMP-4 was
primarily cytosolic rather than membrane-associated (Figure 3B).
Overexpression of TIMP-4 by the U87 cells had no effect on cell
growth rate or morphology (data not shown). 
Treatment of glioma cells with exogenous recombinant TIMP-4
gave similar results as observed with the TIMP-4 overexpressing
cell lines (Figure 3C). Invasion was decreased by ~75% through
Matrigel for U251 cells in the presence of 1 mg ml–1 TIMP-4
compared to the control, vehicle-treated cells. This suggests that,
whether overexpressed or encountered exogenously by glioma
cells, TIMP-4 is a negative regulator of invasive capacity. 
TIMP-4 effects on endothelial cell pro-MMP-2 activation 
TIMP-1 is ineffective as an inhibitor of MT-MMPs, though TIMP-
2 and TIMP-3 both efficiently block these enzymes (Will et al,
1996; Butler et al, 1997). Sequence comparisons show that TIMP-
4 is most closely related to TIMP-2, suggesting that like TIMP-2 it
may be an effective inhibitor of MT-MMP activity. Human umbil-
ical vein endothelial cells (HUVEC) secrete pro-MMP-2 (gelati-
nase-A) and activate the enzyme on the cell surface in response to
stimulation by phorbol ester (PMA) or angiogenic factors via the
action of MT-MMPs (Foda et al, 1996). As shown in Figure 4,
recombinant TIMP-4, like TIMP-2, suppressed PMA-induced pro-
MMP-2 activation in HUVECs, whereas TIMP-1 failed to do so.
This confirms that TIMP-4 is a functional inhibitor of cell surface
MT-MMPs in endothelial cells. HUVECs express very low levels
of TIMP-4 transcripts, as determined by quantitative TaqMan 
RT-PCR (data not shown). Exogenous TIMP-4 also suppressed
pro-MMP-2 activation in glioma (U87) and fibrosarcoma cells
(HT1080, data not shown). 
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To the best of our knowledge this is the only report of TIMP-4 in
gliomas and the most extensive study of the TIMP family in
human gliomas to date. Based on their different patterns of 
expression and localization, our data suggest that TIMPs-1 and -4,
may be involved in the progression of gliomas and that their roles
could be distinct. Other studies have addressed the putative link
between TIMP expression and brain tumours. Mohanam et al
(1995) found TIMP-1 and -2 were down-regulated in GBMs
TIMPs in gliomas 59
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Figure 1 Quantification of TIMP 1–4 mRNAs in gliomas by RT-PCR. Relative levels for mRNAs for each of the four TIMP genes were compared to the
expression of a control gene, GAPDH, in glioma surgical specimens and normal brain tissue using ‘primer-dropping’ RT-PCR. Panel (A) shows a representative
gel analysis of PCR products from 2 samples of normal brain tissue and 6 glioma surgical specimens; LG, low grade; MG, middle grade (includes anaplastic
astrocytomas and malignant oligodendrogliomas); HG, high grade (glioblastoma multiforme). Panel (B) shows the compiled data from the indicated numbers of
specimens, with error bars indicating standard deviations; N, normal brain compared to lower-grade tumours (Mohanam et al, 1995), but we
and others (Nakano et al, 1995; Lampert et al, 1998) found TIMP-
1 expression increases dramatically with glioma malignancy. Also,
TIMP-2 expression does not change with glioma grade (Lampert
et al, 1998) though again there is not universal agreement
(Mohanam et al, 1995; Saxena et al, 1995). While it may not be
relevant in vivo (Rutka et al, 1995) found no correlation between
TIMP-1 and -2 expression and glioma cell invasiveness in vitro.
As in the Lampert et al (1998) study, we found that TIMP-3
expression did not vary with glioma grade; however, one group
found reduced expression by gene silencing via methylation
(Bachman et al, 1999). No published reports to date have
addressed TIMP-4 expression in human brain tumours. 
The precise role of TIMP-1 in glioma pathophysiology is unclear.
The increase in TIMP-1 expression seen in many malignant
neoplasms may be a general consequence of elevated production or
mobilization of growth factors and cytokines in more aggressive
tumours, in much the same way that these stimuli lead to induction
of MMP-9 or activation of MMP-2. Alternatively, since TIMP-1
preferentially binds the pro-enzyme form of MMP-9, upregulation
of this inhibitor in GBM may reflect a specific regulatory mecha-
nism that links these two functions, and could be seen as an attempt
by the host to neutralize increased MMP-9 activity and thus slow
invasion or angiogenesis. It is also possible that TIMP-1 may stimu-
late glioma proliferation directly in vivo since TIMP-1 has erythroid
potentiating activity (EPA), and stimulates proliferation of
numerous cell types (Gasson et al, 1985; Bertaux et al, 1991;
Hayakawa et al, 1992, 1994). Moreover, TIMP-1, but not TIMP-2 or
the synthetic hydroxamate inhibitor BB-94, has been shown to
confer resistance to apoptosis in Burkitt’s lymphoma cells (Guedez
et al, 1998). Fluorescence-tagged TIMP-1 has been visualized
binding to the cell surface of MCF-7 cells, with subsequent translo-
cation to nucleus (Ritter et al, 1999), which may be related to its
growth modulatory effects. Finally, though the mechanism is
unknown, TIMP-1 may upregulate VEGF expression in gliomas, in
60 LL Groft et al
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Figure 2 In situ hybridization analysis of TIMP-1 and TIMP-4 in
glioblastoma multiforme. In situ hybridizations were carried out using
digoxygenin-labelled riboprobes for TIMP-1 and TIMP-4 on a high grade
glioma (glioblastoma multiforme). The TIMP-1 antisense riboprobe (A)
showed strong hybridization to endothelial cells lining the large blood vessel
in the centre of the field and also to surrounding malignant glioma cells.
Panel B shows results with the TIMP-4 antisense riboprobe on a section from
the same tumour, in which hybridization to glioma cells is apparent, but the
blood vessel in the centre of the field shows relatively little staining.
Magnification 400x in both panels. Sense riboprobe controls showed no
signals 
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Figure 3 TIMP-4 inhibits Matrigel invasion of glioma cells. (A) Two
independent TIMP-4 expressing stably transfected U87 glioma cell lines (T4–4
and T4–11) were compared for the ability to invade Matrigel alongside control
pBabe-puro vector control (VC) transfected cells. After 24 hours incubation,
cells present on the undersides of Matrigel-coated filters in modified Boyden
chambers were fixed, haematoxylin counterstained and counted. Assays were
performed in triplicate and 4 random fields at 200x magnification were
counted for each assay. (B) Western blot analysis of TIMP-4 expression by
vector control transfected U87 cells (U87–6) and the T4–4 and T4–11 cell
lines. The panel shows results for cell-associated TIMP-4 following cell
fractionation (M, membrane-associated; C, cytosolic). Similar results were
obtained using conditioned media from the cell lines. (C) Matrigel invasion
assays were carried out for 36 hours using U251 glioma cells, with either 0 or
1 mg ml–1 recombinant murine TIMP-4 (rTIMP-4) added to both the fluid
Matrigel prior to solidification and the medium of the upper chamber. Assays
were performed in triplicate with four 4003 fields counted per assay parallel with its effects on rat mammary carcinoma cell lines
(Yoshiji et al, 1998). Given its potential growth-promoting abilities,
TIMP-1 may actually contribute to glioma malignancy when upreg-
ulated, rather than act as an inhibitor, though our data do not 
distinguish between these two possibilities. However, whatever the
mechanism, our data suggest that TIMP-1 elevation is a marker of
worse clinical outcome in gliomas. 
TIMP-4, the newest member of the TIMP family, has not previ-
ously been studied in brain tumours. In breast cancer overexpres-
sion in vitro and in vivo resulted in decreased invasion, and
microvascular density (Wang et al, 1997). One interpretation of
our data is that TIMP-4 acts in a similar fashion in gliomas, and its
underexpression in highly malignant gliomas allows increased
proliferation, invasion and angiogenesis to occur. Consistent with
this idea, recombinant or over-expressed TIMP-4 had no effect on
cellular viability and proliferation (as measured by 3H-thymidine
incorporation and MTT assays, data not shown), but substantially
reduced the invasive capacity of glioma cells through Matrigel.
Several MMPs have been linked with the invasive behaviour of
malignant gliomas, including MMP-2, MMP-9 and MT1-MMP
(Saxena et al, 1995; Sawaya et al, 1996; Uhm et al, 1996;
Yamamoto et al, 1996; Deryugina et al, 1998; Lampert et al, 1998;
Belien et al, 1999; Forsyth et al, 1999; Price et al, 1999; Raithatha
et al, 2000). In particular there is growing evidence for involve-
ment of several other members of the MT-MMP family including
MT2-MMP (Nakada et al, 1999), MT5-MMP (Llano et al, 1999)
and MT6-MMP (Velasco et al, 2000). Like TIMP-2, TIMP-4 is
able to inhibit a wide range of MMPs, including MT-MMPs, as we
show by its ability to block pro-MMP-2 activation in HUVECs.
Thus, the diminution of TIMP-4 in GBMs compared to lower-
grade tumours, combined with increases in a number of MMPs,
could contribute to a tilt in the proteolytic balance in favour of
increased remodelling and cellular invasion. 
The localization data that we have obtained also suggest distinct
roles for TIMP-1 and -4 in glioma tumorigenesis. The intense
staining in the microvasculature of GBM samples in TIMP-1 in situ
hybridization studies is of particular interest. This not only
contrasts our localization data of TIMP-4, but also our in situ
hybridization data for TIMP-2, where transcript was absent from
vascular structures (data not shown). These data are intriguing, as
previous reports have suggested that TIMP-2 inhibits cytokine-
induced endothelial cell proliferation (Murphy et al, 1993). TIMP-4
overexpression in breast carcinoma cells resulted in less vascular
tumours in vivo (Wang et al, 1997). Several pieces of evidence
suggest that MT-MMPs are effectors of neovascularization,
including the finding that MT1-MMP has been shown to act as a
pericellular fibrinolysin and promote neovessel formation in vitro
(Hiraoka et al, 1998). Moreover MT1-MMP–/– mice show
profound growth abnormalities related to defects in vasculariza-
tion of the growth plate during osteogenesis, and fail to induce
vessel formation in corneal micropocket assays in response to
bFGF (Zhou et al, 2000). Therefore, it is possible that reduced
TIMP-4 expression in vivo could permit increased MT-MMP
activity in the brain microvasculature, leading to increased vessel
growth. This idea is supported by in vitro invasion assays, where
TIMP-4 inhibited VEGF/bFGF induced formation of 3-
dimensional endothelial tube-like structures in fibrin gels 
(M. Lafleur, unpublished observation). Since TIMP-1 does not
inhibit MT-MMPs, its increased presence in endothelial cells in
gliomas would have no impact on MT-MMP-mediated angiogenesis. 
In summary, our data offer evidence for the differential involve-
ment of TIMPs in glioma pathophysiology. Expression and localiza-
tion data for mRNA and protein suggest the roles of TIMP-1 and -4
are very different from each other in gliomas though their precise
functions are not yet known. Expanding our knowledge of how
TIMPs are involved in brain tumour progression will help clarify
glioma biology and potentially lead to gene therapy-based approaches
of TIMP-delivery to reduce both glioma invasion and angiogenesis. 
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